Dr. Antonio Parente was born in Badalona (Barcelona) and has spent most of his professional career in the pharmaceutical industry. He studied chemistry and graduated with a PhD in Organic Chemistry from the University of Barcelona (1978). His academic training includes an MBA from ESADE (1981) and a PADE - Senior Business Management Program - from IESE (2010). He is the co-author of over 40 scientific articles and patents. 

Dr. Parente began his professional career at Laboratorios Vita S.A. in charge of the Chemical and Patents Department. Since 1989, he has co-founded several companies, including Lipotec S.A., BCN Peptides S.A., Diverdrugs S.L., Lipofoods S.A., BCN Corp S.L., and Primaderm S.A., where he has held various positions such as general manager, CEO, and administrative director. In 2000, he co-founded GP Pharm, where he currently serves as Executive Chairman. 

Additionally, Dr. Parente has served as President of the Business Council of CRG (Centre for Genomic Regulation), Vice President of ASEBIO (Spanish Association of Biotechnology Companies), co-founder and President of CataloniaBio (Business Association of Biotechnology Companies of Catalonia), and Vice President of Biocat. Furthermore, he has previously acted as President of the Chemical-Pharmaceutical Section of the Official College of Chemists of Catalonia (1980-1994). Finally, Dr. Parente is an Advisory Director and/or Business Angel for more than 10 Spanish biotechnology companies.

Marta Parente holds a degree in Economics and Business Sciences from Pompeu Fabra University (2005) and an MBA from IESE (2010). She began her professional career in the health and cosmetics sector at the European Union Chamber of Commerce in Beijing, China (2005-2008). After completing her MBA at IESE and spending some time at Janssen Cilag S.A., Madrid, she joined Roche in 2010, working in various areas of the company in different countries (Roche Diagnostics in Sweden, Switzerland, and the USA; Roche Diabetes Care in Italy).

Finally, she joined Genentech, the American branch of Roche Pharmaceuticals, where she was responsible for Global Market Access for skin cancer products in Oncology until 2015; she then led the marketing team for the American market in Oncology; and in 2017, she became Head of Sales for the East/Mid-Atlantic zone of the USA in Oncology at Genentech.

In 2020, she joined GP Pharm as Director of New Projects and Corporate Viability, and in 2021, she assumed the role of COO of GP Pharm. In January 2022, she was appointed CEO of GP Pharm. Marta has been a member of the company's Board of Directors since 2017 and a director of BCN Peptides. In January 2024, she joined the board of CataloniaBio and in May, the board of the L’Hospitalet de Llobregat delegation of the Chamber of Commerce.

Josep de Nadal was born in Barcelona and holds a degree in Chemical Engineering from the Chemical Institute of Sarrià (IQS, 1968) and an MBA from ESADE (1968). He began his professional career as Brand Manager at Danone S.A. (1968-1974), was Head of Division at MasCosmetics (1974-1976), and General Manager of Laboratorios Ausonia (1976-1992).

Josep de Nadal's professional activities from 1992 to 2010 include a wide variety of managerial, executive and consulting positions in various companies, both national and international. Since 2010, Josep de Nadal has been a member of the Board of Directors of Ofistrade, Senior Advisor of Clairfield Corporate Finance, Director of Sosa Ingredients SL, and Independent Director of GP Pharm SA.

Josep de Nadal has also been a Trustee of the IQS Foundation (2006-2008) and Professor of the Master's Degree in Chemical Business Management at IQS (1982-1987). He is currently a member of the Cercle d'Economia and Vice-President of the Fundació Relleu.

Dr. Berta Ponsatí was born in Barcelona and has developed her professional career in the pharmaceutical industry. She has a degree in Chemistry (1983) and a PhD in Organic Chemistry from the University of Barcelona (1985). She has extensive training and experience in peptide chemistry following her studies at the UPC (Universitat Politècnica de Catalunya) and a postdoctoral stay at the CBM (Centre for Molecular Biology) in Madrid.

She began her professional career as director of the peptide synthesis department at Lipotec S.A. (1990). In 2005, she became Managing Director of BCN Peptides S.A. From 2012 to 2021, she was also CEO of GP Pharm SA where she boosted the company's international presence, expanding its activities, such as CDMO, and consolidating its presence in the Spanish market. She is currently an Independent Director of GP Pharm SA.

In addition, Dr. Ponsatí is co-author of multiple scientific articles and patents and has co-directed several doctoral theses in the field of peptide synthesis.

Anna Parente holds a degree in Medicine from the University of Barcelona (2004) and specialised in Haematology and Haemotherapy at the Hospital de Sant Pau, where she completed her residency. She later moved to Norway with a scholarship from Kreftforeningen (Norwegian Cancer Society) to pursue her PhD in Chronic Lymphocytic Leukaemia. Her dissertation was titled "Unravelling the Role of the Microenvironment in Chronic Lymphocytic Leukaemia: T Helper Cell Support of Cancer Cells," conducted with Dr. Ludvig Munthe's group at the University of Oslo (2018).

Subsequently, she joined the Oslo University Hospital as a consultant, specialising in Immunology, where she has worked for the past eight years. Her primary focus has been the Cellular Immunology section, where she diagnoses haematological diseases and primary immunodeficiencies, collaborating with the departments of Infectious Diseases, Paediatrics, Haematology, and Clinical Immunology.

In 2023-24, she completed an Executive Development Programme (PDD) at IESE.